Korsana Biosciences, Inc. — Form 8-K
Filed November 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 88/100
What the filing says
Korsana completed a merger with Cyclerion Therapeutics in September 2026 concurrent with a $380 million private placement, resulting in cash and equivalents of $456.2 million as of Q3 2026—sufficient to fund operations into 2029. The company strengthened leadership (new CMO, CTO, audit chair) and advanced lead program KRSA-028 with Phase 1 healthy volunteer data expected mid-2027 and proof-of-concept data in Alzheimer's patients by year-end 2027 or Q1 2028. Q3 R&D expenses were $42.1 million; net loss was $46.4 million on 55.1 million shares outstanding.
Why this rating
Merger adds $456M cash (80× company market cap) and transformational resources for pre-clinical biotech. Enables 2.5+ year runway and near-term clinical catalysts.
Tradability signal
NO TRADE
No trade: positive news with only -0.7% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.53% over 4 hrs, n=325). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $30.30 | +10 min · unknown $30.29 ▼ 0.03% | +30 min · unknown $30.12 ▼ 0.59% | +1 hr · unknown $29.91 ▼ 1.30% | +4 hrs · unknown $30.13 ▼ 0.58% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.